Received 459 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2023; preliminary net product sales of FILSPARI totaled $15 million for the fourth quarter
Company on track to submit sNDA to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI in IgAN to full approval
CHMP opinion on potential approval of sparsentan for the treatment of IgAN in Europe expected in Q1 2024
Pivotal Phase 3 study of pegtibatinase in classical homocystinuria (HCU) underway
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.